Caregiver's Home Companion Free captioning phone for those with hearing loss.
 HOME PAGE  SEARCH Go

Posted: August 26, 2008

New Prostate Cancer Treatment Shows Promise

New research indicates that giving patients a continuous low dose of an immune system booster -- a method known as metronomic dosing -- as part of a therapeutic prostate cancer vaccine strategy is safe and produces similar immune responses and fewer side effects than the more common dosing method, which is not well tolerated by many patients.

 

The vaccine used in this study, published in the medical journal Clinical Cancer Research, is designed to stimulate an immune response against prostate-specific antigen (PSA), a protein produced by the prostate that is often found at elevated levels in the blood of men who have prostate cancer and some non-cancerous prostate conditions.

advertisement
Discount Prescriptions
 

In the study, researchers at that National Cancer Institute (NCI) examined the side effects and immune responses of patients treated with a three-pronged approach: the vaccine, radiation therapy, and an alternative dosing regimen of an immune system booster, interleukin-2.

 

The patients all had localized prostate cancer, had not undergone surgery to remove the prostate, and were candidates for radiation therapy as their primary form of treatment.

 

"Developing an alternative method of administering vaccine therapy that is well tolerated by most patients and produces similar immune responses to standard methods may help further the development of vaccine therapies for prostate cancer," said Dr. James L. Gulley, of NCI's Center for Cancer Research.

 

Therapeutic cancer vaccines are designed to treat cancer by stimulating the immune system to attack tumor cells without harming normal cells. Several proteins, including PSA, are over-expressed, or produced in excess amounts, by cancer cells and have shown potential to serve as triggers in initiating immune responses.

 

These findings have led to the development of cancer vaccines that target these proteins, also known as tumor-associated antigens. To heighten the body's natural defenses, immune system boosters, such as IL-2, are often given with the vaccines. IL-2 administration, however, is frequently associated with substantial side effects, including fatigue and high blood sugar.

 

In a previous study involving the same prostate cancer vaccine, IL-2 was given to 19 patients daily for five days during each 28-day vaccine treatment cycle. However, a large majority of the patients had to have the dose of IL-2 reduced or discontinued, primarily because of fatigue.

 

In this new study, the researchers sought to decrease the side effects associated with IL-2. To do this, the team treated 18 patients with the vaccine and radiation therapy, but with lower doses of IL-2 given over a longer period of time. The patients received the same total amount of IL-2 as in the previous study, but it was administered in smaller daily doses for 14 days of each 28-day treatment cycle.

 

With metronomic dosing, less than a quarter of the patients had side effects that required their dose of IL-2 to be reduced.

 

"Based on safety and feasibility, metronomic dosing appears to be superior to standard dosing and administration," said Gulley. "More research is needed to evaluate the efficacy of this dosing method in treating prostate cancer."

 

(Article courtesy of ConsumerAffairs.com)

Email or share this story Bookmark and Share

Search CaregiversHome
Find with keyword(s):

Enter a keyword or phrase to search CaregiversHome's archives for related news topics, the latest news stories, timely times, and reference articles.

© 2008 Pederson Publishing, Inc. All Rights Reserved.
Commercial use, redistribution or other forms of reuse of this information is strictly prohibited without the prior written permission of Pederson Publishing.

_____

View The Caregiver's Hotline in which this article first appeared

Back to Top

Privacy Statement Contact Us Site Map Products & Services Our Partners Advertise
© Copyright 2003-2020. Pederson Publishing, Inc. All rights reserved.